Is Adeshwar Meditex overvalued or undervalued?

As of 13 November 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade, indicating a more favorable outlook for the company. The stock is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 11.33, an EV to EBITDA of 6.75, and a Price to Book Value of 0.62, which suggest that the company is trading at a significant discount relative to its earnings and asset value.
In comparison to its peers, Adeshwar Meditex stands out with a much lower PE ratio than Poly Medicure, which has a PE of 55.2, and Blue Jet Health at 28.63. The EV to EBITDA ratio of 6.75 also highlights its attractiveness compared to other expensive peers like Laxmi Dental at 38.93. Despite the recent underperformance of Adeshwar Meditex's stock against the Sensex, with a YTD return of -37.5% compared to the Sensex's 8.11%, the current valuation metrics suggest that it presents a compelling investment opportunity.